XBiotech
PUBLIC
STATUS
51-60
EMPLOYEES
XBIT
STOCK SYMBOL
$23.28
SHARE PRICE
(As of Monday Closing)
Description
XBiotech Inc is an US based clinical-stage biopharmaceutical company which is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing MABp1 a therapeutic antibody as a treatment for cancer. It has developed therapeutic antibody Xilonix which is being evaluated as a monotherapy to treat advanced stages of colorectal cancer. Xilonix neutralizes a pro-inflammatory protein produced by leukocytes and other cells.
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
- 8201 E Riverside Drive
- Building 4 Suite 100
- Austin, TX 78744
- United States
+1 (512) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore XBiotech’s full profile, request a free trial.
XBiotech Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $5.44 - $26.40 | $956M | $23.20 | -$0.64 | 618K | 41.1M |
XBiotech Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 384,059 | 161,115 | 100,648 | 281,740 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (22,074) | (19,105) | (32,020) | (52,112) |
| Net Income | (23,977) | (21,138) | (33,150) | (52,761) |
| Total Assets | 66,643 | 44,345 | 62,972 | 67,050 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
XBiotech Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore XBiotech‘s full profile, request access.
Request full access to PitchBookXBiotech Competitors (92)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BeiGene | Formerly PE-Backed | Beijing, China | 0000 | 00.000 | 000000000 | 00.000 |
| 000 000000000000 | Venture Capital-Backed | Epalinges, Switzerland | 000 | 00000 | 00000000 | |
| 000000000 00000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Corporation | San Diego, CA | 00 | 00000 | 000000 - 000 | 00000 |
| 00000 00000 000000 | Venture Capital-Backed | Geneva, Switzerland | 000 | 00000 | 0000000000 0 | 00000 |
XBiotech Executive Team (2)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| John Simard | Chief Executive Officer & Chairman | ||
| Sushma Shivaswamy | Chief Scientific Officer |
XBiotech Board Members (1)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 0000 000000 | XBiotech | Chief Executive Officer & Chairman | 000 0000 |